Merus N.V.

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
52.95 ^USD	-0.26%		-7.09%	+92.55%

02/07	Merus N.V. Announces Chief Medical Officer Changes	CI
01/07	Sector Update: Health Care Stocks Retreat Late Afternoon	MT

Merus N.V. Announces Resignation of John J. Crowley as the Executive Vice President and Chief Financial Officer

January 03, 2019 at 02:36 am IST

On January 2, 2019, John J. Crowley resigned as the Executive Vice President and Chief Financial Officer of Merus N.V. to pursue other opportunities.

Latest news about Merus N.V.

Merus N.V. Announces Chief Medical Officer Changes	02/07	CI
Sector Update: Health Care Stocks Retreat Late Afternoon	02/07	MT
Merus Names New Chief Medical Officer	01/07	MT
Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating	17/06	MT
Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing	13/06	MT
BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating	04/06	MT
Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating	04/06	MT
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment	04/06	MT
Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating	03/06	MT
Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting	02/06	CI
Merus Prices $400.2 Million Public Share Offering	30/05	MT
BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating	29/05	MT
HC Wainwright Adjusts Price Target on Merus to $85 From $65, Maintains Buy Rating	29/05	MT
Merus Launches $300 Million Stock Offering	29/05	MT
Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating	28/05	MT
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating	28/05	MT
Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating	28/05	MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon	25/05	MT
Top Midday Gainers	24/05	MT
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities	24/05	MT
BofA Adjusts Price Target on Merus to $61 From $52, Maintains Buy Rating	24/05	MT
Top Premarket Gainers	24/05	MT
Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab	13/05	MT
Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation	13/05	DJ
Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA	13/05	CI

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Merus N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.95 USD

Average target price

86.27 USD

Spread / Average Target

+62.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MERUS N.V.	+92.55%	350.73Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+18.75%	2.59TCr
BIONTECH SE	-24.33%	1.93TCr
GENMAB A/S	-19.54%	1.6TCr
BEIGENE, LTD.	-17.95%	1.57TCr
WUXI APPTEC CO., LTD.	-46.81%	1.49TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.45TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.39TCr

Bio Therapeutic Drugs

Merus N.V.

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Merus N.V. Announces Resignation of John J. Crowley as the Executive Vice President and Chief Financial Officer

Latest news about Merus N.V.

Chart Merus N.V.

Company Profile

Income Statement Evolution

Ratings for Merus N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs